BRANFORD, Conn.--(BUSINESS WIRE)--454 Life Sciences, a part of Roche Applied Science, today announced that researchers from The International Mesothelioma Program at Brigham and Women’s Hospital and Harvard Medical School in Boston have used the 454 long-read sequencing technology to characterize for the first time mutations in expressed genes unique to malignant pleural mesotheliomas (MPMs). The 454 Sequencing system was used to comprehensively investigate the transcriptomes of 4 MPMs and two control tissues. The data revealed a number of genes which could be causally related to cancer including XRCC6, PDZK1IP1, ACTR1A, and AVEN. The study appeared today, in the Proceedings of the National Academy of Sciences.
